Lifesci Capital Has Positive Outlook of CMPS Q2 Earnings

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Analysts at Lifesci Capital lifted their Q2 2026 earnings estimates for shares of Compass Pathways in a research note issued to investors on Tuesday, June 2nd. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings per share of ($0.35) for the quarter, up from their previous estimate of ($0.50). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($1.24) per share.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15.

CMPS has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Jefferies Financial Group upgraded shares of Compass Pathways to a “strong-buy” rating in a research note on Tuesday, May 5th. Morgan Stanley increased their target price on shares of Compass Pathways from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. BTIG Research reiterated a “buy” rating and issued a $14.00 target price on shares of Compass Pathways in a research note on Wednesday, May 13th. Finally, Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Compass Pathways has an average rating of “Moderate Buy” and an average target price of $21.36.

Compass Pathways Stock Down 4.8%

CMPS opened at $12.69 on Thursday. The company has a 50 day moving average of $8.70 and a 200 day moving average of $7.30. The company has a market cap of $1.71 billion, a PE ratio of -4.03 and a beta of 2.50. Compass Pathways has a 12 month low of $2.25 and a 12 month high of $14.76. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15.

Institutional Trading of Compass Pathways

Institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its position in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Compass Pathways during the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Compass Pathways during the 4th quarter valued at $47,000. Advisory Services Network LLC purchased a new stake in shares of Compass Pathways during the 3rd quarter valued at $41,000. Finally, Parallel Advisors LLC raised its position in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.